Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis
Conclusions:
This study will provide new evidence for clinical profile of NOACs on SSE, major bleeding, all-cause death, and NCB in CKD patients.
PROSPERO registration number:
CRD42019116940.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
More News: Atrial Fibrillation | Bleeding | Chronic Kidney Disease | Clinical Trials | Coumadin | Databases & Libraries | Internal Medicine | Stroke | Study | Urology & Nephrology | Vitamin K | Vitamins | Warfarin | Websites